COMPASS Pathways plc
NASDAQ Global Select•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Kabir Kumar Nath
- Full Time Employees
- 166
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- 33 Broadwick Street London United Kingdom W1F 0DQ
- IPO Date
- Sep 18, 2020
- CIK
- 0001816590
- Website
- compasspathways.com
- Similar Companies
- Business
- COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
Company News
Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET
COMPASS Pathways (CMPS) Upgraded to Buy: Here's Why
Compass Pathways Stock: Downgrading To Hold On Released TRD Results With COMP360
Compass Pathways' late-stage psilocybin trial targeting treatment-resistant depression meets primary endpoint
Vizsla Silver, COMPASS Pathways And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Compass Pathways stock slip as psilocybin depression trial falls short of expectations
Compass Pathways' depression drug succeeds late-stage trial
Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
Meta to roll out AI-powered ad creation by late 2025, says WSJ
COMPASS Pathways (CMPS) Upgraded to Buy: Here's What You Should Know
Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference
COMPASS Pathways plc (CMPS) Q1 2025 Earnings Call Transcript
Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights
Compass Pathways Establishes Strategic Collaboration with HealthPort to Inform the Potential Delivery of COMP360 Synthesized Psilocybin Treatment in Underserved Communities
Compass Pathways to Announce First Quarter Financial Results on May 8, 2025
Why Compass Pathways Stock Was a Double-Digit Winner This Week
Compass Pathways Announces Dosing Complete for All Participants in Part A of Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
This Is a Test From GlobeNewswire
Compass Pathways Announces Completion of Recruitment for the Phase 3 COMP005 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
Compass Pathways Announces Publication of Results from COMP004 Study on COMP360 Psilocybin for Treatment-Resistant Depression